Neoprobe holds the exclusive rights to Lymphoseek under license from University of California, San Diego for use in diagnostic applications such as lymphatic mapping as well as in ultrasound and optical imaging.
Lymphoseek is a proprietary radioactive lymphatic mapping targeting agent being developed by Neoprobe for use with handheld gamma detection devices, such as Neoprobe’s neo2000 system. After achieving positive efficacy results in recently completed Phase II multicenter clinical trials for Lymphoseek, Neoprobe is now moving forward with preparations for two Phase III clinical trials, one in breast cancer and one in melanoma.